H. Trent Spencer, Ph.D.
Dr. Spencer received his Ph.D. in Biochemistry from Creighton School of Medicine in Omaha. His postdoctoral studies at St. Jude Children's Research Hospital focused on drug resistance gene therapy and in vivo selection of genetically-modified cells. He is currently Director of the Cell and Gene Therapy Program and Associate Professor within the Aflac Cancer and Blood Disorders Center at Emory University. His previous affiliations include an Assistant Professorship in the South Carolina Cancer Center/Department of Biological Sciences, University of South Carolina and Assistant Director of the Molecular Genetics Graduate Program. He has headed a well-funded gene therapy laboratory for over 10 years. His research interests continue to be the development of gene therapy applications for the treatment of cancer and inherited diseases.
Christopher B. Doering, Ph.D.
Chief Scientific Officer
Dr. Doering received his B.S. in zoology from the University of Texas, Austin and his Ph.D. in genetics and molecular biology from Emory University. Chris has a longstanding interest in coagulation factor VIII biology stemming from his postdoctoral studies characterizing recombinant porcine, murine and bioengineered factor VIII molecules. Currently, he is Associate Professor of Pediatrics in the Aflac Cancer and Blood Disorders Center. As a trained molecular biologist and experimental hematologist with more than 20 years of research experience in gene and protein expression, his overall scientific interest has centered on the development of gene therapy and protein engineering strategies for genetic diseases and cancers. Current areas of research involve the development of pharmaceutically-inspired coagulation factors, general approaches to viral vector genome engineering, and cancer gene therapy approaches involving genetically-engineered innate immune cells as well as exotic chimeric antigen receptors. Within the past few years, his lab has published articles in Nature Biotechnology, Nature Communications, Molecular Therapy, Blood, and Journal of Thrombosis and Hemostasis.
Mohan Rao, Ph.D.
Chief Financial Officer
Dr. Rao is a Managing Director at Epsilon Economics and an Adjunct Professor in the Department of Industrial Engineering and Management Sciences at Northwestern University. He has expertise with the economics of factor VIII. Dr. Rao has a Ph.D. from the University of Colorado and a pre-doctoral fellowship from Harvard University. Dr. Rao serves on the Board of Directors of the Children’s Memorial Hospital in Chicago, on the Board of Trustees of the Rotary/One Foundation, and is a member of the Economic Club of Chicago.
John S. (Pete) Lollar ||| , M.D.
Dr. Lollar received his medical degree at St. Louis University and underwent residency and fellowship training in Internal Medicine and Hematology & Oncology at the University of Iowa and at the Mayo Clinic. He has conducted research on the structure and function of the factor VIII - von Willebrand factor complex, the assembly of the intrinsic pathway factor X activation complex, the immune response to factor VIII and the biosynthesis of factor VIII. He is the inventor of Obizur, a recombinant factor VIII product used to treat individuals with inhibitory antibodies to factor VIII. He currently is Hemophilia of Georgia Professor of Pediatrics at Emory University.
Gabriela Denning, Ph.D
Head of Research & Development
Dr. Denning received her Ph.D. in Biochemistry from The University of Texas Medical Branch. Her post-doctoral studies at The Scripps Research Institute under Dr. Peter K. Vogt, focused on understanding novel mechanisms of PTEN tumor suppressor function. Currently, Dr. Denning oversees all pre-clinical research and development efforts at Expression Therapeutics. Dr. Denning oversees many company roles including directing the development and execution of NIH STTR and SBIR funded programs in lentiviral and adeno-associated viral gene therapy of hemophilia A as well as recombinant ET3i immune tolerance induction for FVIII inhibitors.